跳至主要内容
临床试验/NCT00002060
NCT00002060已完成不适用

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)

Newport Pharmaceuticals International2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
2

研究概览

简要总结

The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS. Secondly, to determine the effect of Isoprinosine in decreasing the severity and/or incidence of lesser opportunistic infections and/or other conditions associated with ARC.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Exclusion Criteria
  • Concurrent Medication:
  • Cardiac glycosides.
  • Patients with the following are excluded:
  • Presenting with chronic candida infection-colo/rectal, oral/pharyngeal, cutaneous (finger/toenails) - for = or > 3 months who have not responded to therapy.
  • Critical illness.
  • Hemophilia.
  • Prior Medication:
  • Excluded within 1 month of study entry:
  • Steroids.
  • Cytotoxic immunosuppressive agents.
  • Radiotherapy and/or systemic antiviral medication.
  • Immunomodulators (including Isoprinosine).
  • Prior Treatment:
  • Excluded within 1 month of study entry:
  • Radiotherapy.
  • History of gout, uric acid urolithiasis, uric acid nephrolithiasis, or renal dysfunction.
  • Lymphoid malignancy.
  • Homosexual male patients with AIDS related complex (ARC).
  • Current IV drug abuse.

排除标准

  • 未提供

研究者

发起方
Newport Pharmaceuticals International
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验

A Multi-Center Randomized Double-Blind... | 临床试验